Glycerol phenylbutyrate

(Ravicti®)

Ravicti®

Drug updated on 1/4/2024

Dosage FormLiquid (oral; 1.1 g/mL)
Drug ClassNitrogen-binding agent
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements.

Product Monograph / Prescribing Information

Document TitleYearSource
Ravicti (glycerol phenylbutyrate) Prescribing Information.2021Horizon Therapeutics USA, Inc. Deerfield, IL

Clinical Practice Guidelines

Document TitleYearSource
Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision.2019Journal of Inherited Metabolic Disease